

# DIN EN ISO 11615:2018-04 (E)

## Health informatics - Identification of medicinal products - Data elements and structures for the unique identification and exchange of regulated medicinal product information (ISO 11615:2017)

---

<b>Contents</b>		Page
<b>European foreword</b>		5
<b>Foreword</b>		6
<b>Introduction</b>		7
<b>1 Scope</b>		9
<b>2 Normative references</b>		9
<b>3 Terms, definitions and abbreviated terms</b>		10
<b>4 Message exchange format</b>		21
<b>5 Conformance terminology and context as it relates to the ISO IDMP standards and corresponding IDMP technical specifications</b>		22
<b>6 Concepts required for the unique identification of Medicinal Products</b>		22
6.1	General considerations	22
6.2	Authorised Medicinal Products	22
6.3	Investigational Medicinal Products	23
6.4	Concepts required for the unique identification of a Medicinal Product and the association with PhPID(s)	23
6.5	Concepts required for the unique identification of Medicinal Products and the association with the marketing authorisation number	23
6.6	Concepts required for the unique identification of Medicinal Products and the association with data carrier identifiers	24
<b>7 Description of the information modelling principles and practices</b>		25
7.1	General considerations	25
7.2	Conceptual overview diagrams	25
7.3	High-level diagrams	26
7.4	Detailed description diagrams	26
7.4.1	General	26
7.4.2	Relationships between classes	27
7.4.3	Attributes of classes	28
7.4.4	Generalised classes and patterns	28
7.4.5	Translation and language	28
<b>8 Identifying characteristics for authorised Medicinal Products</b>		28
8.1	Primary identifiers — General considerations	28
8.2	Medicinal Product Identifier (MPID)	29
8.2.1	General considerations	29
8.2.2	MPID code segments	29
8.3	Packaged Medicinal Product Identifier (PCID)	30
8.3.1	General considerations	30
8.3.2	Package description (PCID) code segment	31
8.4	Medicinal Product Batch Identifier (BAID1)	31
8.5	Medicinal Product Batch Identifier (BAID2)	31
<b>9 Information for an authorised Medicinal Product</b>		32
9.1	Authorised Medicinal Product — Information overview	32
9.1.1	General	32
9.1.2	Medicinal Product	32

9.1.3	Medicinal Product name .....	32
9.1.4	Header .....	33
9.1.5	Manufacturer/Establishment (organisation) .....	33
9.1.6	Marketing authorisation .....	33
9.1.7	Packaged Medicinal Product .....	33
9.1.8	Pharmaceutical product .....	33
9.1.9	Ingredient .....	33
9.1.10	Clinical particulars .....	33
9.2	Medicinal Product .....	33
9.2.1	General .....	33
9.2.2	Detailed description of Medicinal Product information .....	34
9.3	Marketing authorisation .....	36
9.3.1	General .....	36
9.3.2	Detailed description of marketing authorisation information .....	41
9.4	Organisation .....	46
9.4.1	General .....	46
9.4.2	Detailed description of organisation information .....	46
9.5	Manufacturer/Establishment (organisation) .....	49
9.5.1	General .....	49
9.5.2	Detailed description of manufacturer/establishment (organisation) information .....	49
9.6	Packaged Medicinal Product, including manufactured item and device .....	50
9.6.1	General .....	50
9.6.2	Detailed description of Packaged Medicinal Product information .....	51
9.7	Ingredient, substance and strength .....	60
9.7.1	General .....	60
9.7.2	Detailed description of ingredients, substance and strength information .....	60
9.8	Pharmaceutical product and device .....	63
9.8.1	General .....	63
9.8.2	Detailed description of pharmaceutical product and device information .....	63
9.9	Clinical particulars .....	65
9.9.1	General .....	65
9.9.2	Detailed description for clinical particulars information .....	66
<b>10</b>	<b>Identifying characteristics for Investigational Medicinal Products .....</b>	<b>70</b>
10.1	General .....	70
10.2	Primary identifiers .....	70
10.2.1	General considerations .....	70
10.3	Investigational Medicinal Product Identifier (IMPID) .....	71
10.3.1	General considerations .....	71
10.3.2	IMPID code segments .....	71
10.4	Investigational Medicinal Product Package Identifier (IPCID) .....	72
10.4.1	General provisions .....	72
10.4.2	Package description code segment .....	72
10.5	Investigational Medicinal Product Batch Identifier (BAID1) .....	73
10.6	Investigational Medicinal Product Batch Identifier (BAID2) .....	73
<b>11</b>	<b>Information for an Investigational Medicinal Product .....</b>	<b>73</b>
11.1	General .....	73
11.2	Conceptual overview of the information for an Investigational Medicinal Product .....	73
11.2.1	General .....	73
11.2.2	Investigational Medicinal Product .....	74
11.2.3	Investigational Medicinal Product name .....	74
11.2.4	Header .....	74
11.2.5	Manufacturer/Establishment (organisation) .....	74
11.2.6	Clinical trial authorisation .....	75
11.2.7	Investigational Packaged Medicinal Product .....	75
11.2.8	Pharmaceutical product .....	75
11.2.9	Ingredient .....	75
11.2.10	Clinical particulars .....	75

11.3	Investigational Medicinal Product .....	75
11.3.1	General.....	75
11.3.2	Detailed description of Investigational Medicinal Product information.....	75
11.4	Clinical trial authorisation .....	78
11.4.1	General.....	78
11.4.2	Detailed description of clinical trial authorisation information.....	78
11.5	Manufacturer/Establishment (organisation).....	82
11.6	Investigational Packaged Medicinal Product.....	82
11.7	Pharmaceutical product.....	80
11.7.1	General.....	80
11.7.2	Pharmaceutical product.....	81
11.7.3	Dosing and route of administration .....	81
11.8	Ingredient.....	81
11.9	Clinical particulars.....	82
11.10	PhPID sets .....	82
11.11	Device nomenclature.....	82
11.12	Device batch identifier .....	82
11.13	Physical characteristics .....	82
11.14	Other characteristics.....	82
	<b>Annex A (normative) Full model — Authorised Medicinal Products detailed diagram.....</b>	<b>83</b>
	<b>Annex B (normative) Full model — Investigational Medicinal Products detailed diagram .....</b>	<b>84</b>
	<b>Bibliography .....</b>	<b>85</b>